dc.creator | Kopanja, Đurđica | |
dc.creator | Zrilić, Mira | |
dc.creator | Kundaković, Tatjana | |
dc.date.accessioned | 2024-01-22T15:00:40Z | |
dc.date.available | 2024-01-22T15:00:40Z | |
dc.date.issued | 2019 | |
dc.identifier.uri | https://farfar.pharmacy.bg.ac.rs/handle/123456789/5499 | |
dc.description.abstract | In 2017, there were 36 543 patients with cancer
in the hospitals in Republic of Srpska (RS). The trend for the growth of diseased patients of
younger age is evident.The costs for cytostatics in 2017 year amounted
to 14,31millions EUR. Procurement of cytostatics at the tertiary level of
healthcare is provided through the Health
Insurance Fund of Republic of Srpska and has
been conducted through public procurement. Very often there are the shortages of cytostatics
in the hospitals. The patients are forced to take over the
procurement of these drugs themselves. Patients are forced to buy drugs in other
countries. | sr |
dc.language.iso | en | sr |
dc.publisher | International Pharmaceutical Federation (FIP) | sr |
dc.rights | openAccess | sr |
dc.source | 79th FIP World Congress of Pharmacy and Pharmaceutical Sciences, 22-26 September, 2019. Abu Dhabi, United Arab Emirates | sr |
dc.subject | cytostatics | sr |
dc.subject | Republic of Srpska | sr |
dc.title | Procurement of Cytostatics in the Republic of Srpska | sr |
dc.type | conferenceObject | sr |
dc.rights.license | ARR | sr |
dc.description.other | FIP 2019 Abu Dhabi | sr |
dc.description.other | Poster presentation | |
dc.identifier.fulltext | http://farfar.pharmacy.bg.ac.rs/bitstream/id/15503/Procurement_of_cytostatics_pub_2019.pdf | |
dc.identifier.rcub | https://hdl.handle.net/21.15107/rcub_farfar_5499 | |
dc.type.version | publishedVersion | sr |